Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial

The combination of lenalidomide and low-dose dexamethasone is an effective treatment for multiple myeloma (MM). Addition of alkylating agents to lenalidomide or thalidomide results in increased response rates and deeper responses. We designed this trial to study the combination of cyclophosphamide,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kumar, Shaji K., Lacy, Martha Q., Hayman, Suzanne R., Stewart, Keith, Buadi, Francis K., Allred, Jacob, Laumann, Kristina, Greipp, Philip R., Lust, John A., Gertz, Morie A., Zeldenrust, Steven R., Bergsagel, P. Leif, Reeder, Craig B., Witzig, Thomas E., Fonseca, Rafael, Russell, Stephen J., Mikhael, Joseph R., Dingli, David, Rajkumar, S. Vincent, Dispenzieri, Angela
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3901994/
https://ncbi.nlm.nih.gov/pubmed/21630308
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.22053
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados